Bankinter S.A. - Pangaea Oncology (ES0105221008) PANGAEA ONCOLOGY: important contract. Good news for 2018 (Bankinter Securities)

Report

Bankinter S.A.

Javier Hombria

PANGAEA ONCOLOGY: important contract. Good news for 2018 (Bankinter Securities)

Yesterday after the market closed, Pangaea Oncology announced it had signed a €870k contract (c. 11.5% of 2017e revenues) with Bioven Europe Limited. With this contract, Pangaea Oncology will be the sole project manager, for the first time, of the clinical trial of a lung cancer treatment

24/10/2017 3 EN

Underlying

Pangaea Oncology

See profile

ES0105221008 Spain

Provider

Bankinter S.A.

Bankinter S.A. is a Spanish brokerage firm established in 1989. The company's line of business includes the provision of market research and trading services for Equity and Fixed Income products.

See profile

Analysts

Javier Hombria

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Fundamental Research

Feasibility Study Results in December to be a Catalyst for this Junior

EUR 18.75

November 25, 2019 November 25, 2019 14 EN

Reig Jofre: EBITDA maintains its growth in 1H20 (+40%) driven by sales (+25%) and cost efficiencies

Reig Jofre: EBITDA maintains its growth in 1H20 (+40%) driven by sales (+25%) and cost efficiencies Growth in sales and EBITDA fuelled by the COVID-19 effect and the Bioibérica acquisition The key features are organic growth of +10%, a higher EBITDA margin and the COVID-19 vaccine Valuation

July 29, 2020 July 29, 2020 17 EN

Pedro Echeguren

Pedro Echeguren

Reig Jofre: EBITDA increased +43% in 1Q20 fuelled by sales (+26%) and a higher EBITDA margin

Growth in sales and EBITDA accelerated in 1Q20 fuelled by the COVID-19 effect The key features are organic growth of +10%, a higher EBITDA margin and lower capex Valuation

May 13, 2020 May 13, 2020 16 EN

Pedro Echeguren

Pedro Echeguren

Reig Jofre: EBITDA (adj.) +17% in 2019 and guidance is 2x in a five-year plan

Growth in sales and adjusted EBITDA accelerated in 2019 after a strong 4Q19 Higher margins coupled to lower capex in the coming years to boost free cash flow Valuation

March 12, 2020 March 12, 2020 16 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

PANGAEA ONCOLOGY: important contract. Good news for 2018 (Bankinter Securities)

Monthly LMI Update Independent Investment Research

Feasibility Study Results in December to be a Catalyst for this Junior

Reig Jofre: EBITDA maintains its growth in 1H20 (+40%) driven by sales (+25%) and cost efficiencies

Reig Jofre: EBITDA increased +43% in 1Q20 fuelled by sales (+26%) and a higher EBITDA margin

Reig Jofre: EBITDA (adj.) +17% in 2019 and guidance is 2x in a five-year plan

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe